Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Earnings Results, Misses Estimates By $0.01 EPS

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) posted its quarterly earnings results on Tuesday. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01), FiscalAI reports. The firm had revenue of $1.73 million for the quarter, compared to analysts’ expectations of $3.60 million. Lineage Cell Therapeutics had a negative return on equity of 76.13% and a negative net margin of 436.47%.

Here are the key takeaways from Lineage Cell Therapeutics’ conference call:

• Management said OpRegen remains on track in a partner-run open-label GA study, citing expanded site activations and Roche/Genentech language describing the program as potentially disease-modifying. They also highlighted long-term data showing vision gains persisted for at least three years after a single dose in the target location.
• The company emphasized major progress at its AlloSCOPE manufacturing platform, which now supports multiple new programs and could enable low-cost, scalable cell production. Management said this platform is a key differentiator because it focuses on reproducible manufacturing before clinical testing.
• COR1, Lineage’s wholly owned corneal endothelial cell program, advanced into preclinical development after the team successfully manufactured off-the-shelf cells meeting internal identity, morphology, and function criteria. Management plans to move the program into translational studies and then initial human testing.
• The ILT1 diabetes initiative is progressing through scale-up work for undifferentiated pluripotent cells, with management reporting the first internal manufacturing milestone was met. The company stressed that the main risk is proving large-scale manufacturing and differentiation can work reliably, and that this remains a stepwise go/no-go process.
• ReSonance reached an important manufacturing milestone with three successful engineering runs and a new deafening model to support functional testing. Lineage also said its Demant partnership is progressing well and that it expects to move toward GMP material and eventual FDA discussions for human testing.
• Financially, Lineage ended the quarter with $53.4 million in cash, which it says funds operations into Q2 2028. First-quarter revenue rose to $1.7 million, while operating expenses increased to $9.3 million, contributing to a net loss of $4.8 million.

Lineage Cell Therapeutics Trading Up 1.5%

Shares of Lineage Cell Therapeutics stock opened at $1.33 on Wednesday. The business’s fifty day moving average price is $1.58 and its 200 day moving average price is $1.67. Lineage Cell Therapeutics has a twelve month low of $0.45 and a twelve month high of $2.09. The stock has a market capitalization of $331.57 million, a P/E ratio of -4.75 and a beta of 1.60.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several large investors have recently made changes to their positions in the business. Marshall Wace LLP acquired a new stake in Lineage Cell Therapeutics during the fourth quarter worth about $2,275,000. Goldman Sachs Group Inc. boosted its stake in Lineage Cell Therapeutics by 894.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,438,746 shares of the company’s stock valued at $2,403,000 after acquiring an additional 1,294,070 shares during the period. Jane Street Group LLC boosted its stake in Lineage Cell Therapeutics by 494.7% in the fourth quarter. Jane Street Group LLC now owns 1,004,794 shares of the company’s stock valued at $1,678,000 after acquiring an additional 835,831 shares during the period. Vanguard Group Inc. grew its holdings in shares of Lineage Cell Therapeutics by 6.2% during the third quarter. Vanguard Group Inc. now owns 9,006,930 shares of the company’s stock valued at $15,222,000 after purchasing an additional 524,057 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Lineage Cell Therapeutics by 26.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,404,800 shares of the company’s stock valued at $4,016,000 after purchasing an additional 499,167 shares during the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. B. Riley Financial lifted their price target on shares of Lineage Cell Therapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, March 24th. Canaccord Genuity Group began coverage on Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, May 4th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $6.25.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.